Kronos Bio
ClosedPioneering precision oncology
San Mateo, United States · Founded 2017 · $260.0M raised
- Headquarters
- San Mateo, California
- Employees
- 1–10
- Founded
- 2017
- Business Model
- B2B
- Website
- kronosbio.com
- Total Funding
- $260.0M
- Last Round
- $155.0M Series BAug 2020
- Rounds
- 2
About
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target deregulated transcription factors to treat cancer and other diseases.
Summary
Kronos Bio is a Biotech company based in San Mateo, United States, founded in 2017. It has raised $260.0M in total across 2 rounds, most recently a $155.0M Series B round in Aug 2020. Investors include Perceptive Advisors, Vida Ventures and Omega Funds.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...